KARIPHARMA
ActiveSummary
KARIPHARMA has been active since 2003 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €632,727 and a net result of €108,353. Equity has been growing by about 4.4% per year since 2018. Its solvency ranks better than 79% of 2,816 sector peers (NACE 82, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Overview
Official details
Source: KBO- Status
- Active since 21-03-2003 Normal situation
- Activity
- Other business support services NACE 82990
- Establishment unit
- 2.355.917.291 1742 Ternat, since 21-03-2003
- Financial year end
- 31 December
- Peppol
- Reachable since 17-09-2025
Board and ownership
- PharmadaDirector · permanent representative Kristel Broechoven
- Pharmada100%2025 annual accounts of Pharmada
- Holdings
- Shares in 1 company APOTHEEK BROECHOVEN
Financial position
- Bankruptcy probabilitywithin 12 months
- < 0.1%
- Gross margin
- €129,534
- Turnover
- ≈ €190,000
- estimated
- Profit
- €108,353
- Equity
- €632,727
- ▲ 0.1%
- Total assets
- €827,778
- ▼ 4.2%
Score breakdownraises riskLiquidity: current ratio 0.35, cash €41,083, halvedlowers riskSize: total assets €827,778Equity €632,727 (76.4% of total assets)Sector: Office administrative, office support and other business support activities (NACE 82)Show the evidence
Checked score
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 82, micro). It does better than 88% of them on solvency, 32% on liquidity, 59% on profitability and 40% on growth.
The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 34 days before the deadline. In the sector (NACE 82), the median for financial year 2024 was 7 days before the deadline, and 35% of those companies filed late.
Searched, nothing found (2)
Key points
- Positive: Back in profit in 2025after a loss of €35,216 in 2024 €108,353 View
- Positive: 8th largest company by equity in Ternat, Administrative and support services sectorin the Checked rankings No. 8 View
- Positive: Filed on time since financial year 2018accounts within the deadline every year 8 years View
Recent changes
- · Gazette deed Resignations: An Broechoven (director) and Kristel Broechoven (director)Appointment: BV Pharmada (director) · Permanent representative: Kristel Broechoven
- · Gazette deed Appointment: PHARMADA (director)Permanent representative: BROECHOVEN Kristel
- · Gazette deed Incorporation
Comparable companies
These companies have the same main activity as KARIPHARMA: other business support services (NACE 82990). They are comparable in size and age: total assets between €722,000 and €896,000, founded between 2000 and 2003.
| Company | Total assets | Gross margin |
|---|---|---|
| KARIPHARMA Ternat | €827,778 | €129,534 |
| GANICOR EUROPE Gent | €847,206 | €122,018 |
| SVP DIENSTENCENTRUM Genk | €758,135 | €126,454 |
| MOOREA PROJECTS Bree | €727,597 | €145,189 |
| LIBERO FINANCIAL AND BUSINESS CONSULTANCY Zandhoven | €895,809 | €122,210 |
| JOCHAN Kapellen | €722,034 | €148,317 |
| EXILE Koksijde | €857,054 | €107,858 |
Key facts about KARIPHARMA
- What is the company number of KARIPHARMA?
- The company number of KARIPHARMA is 0479.817.428. The VAT number is the same number with BE in front: BE 0479.817.428.
- Where is KARIPHARMA based?
- The registered office is at Kerkstraat 14, 1742 Ternat.Company details
- What does KARIPHARMA do?
- According to the KBO register, the main activity is other business support services (NACE 82990).
- What is the legal form of KARIPHARMA?
- The legal form of KARIPHARMA is Private limited company (BV).
- When was KARIPHARMA founded?
- KARIPHARMA was founded on 21-03-2003.
- Is KARIPHARMA still active?
- Yes, KARIPHARMA is an active enterprise in the KBO register.
- What is the turnover of KARIPHARMA?
- The turnover in financial year 2025 is ≈ €190,000. This figure is estimated from the gross margin of €129,534 and 31 comparable companies (NACE 82990). It probably lies between €150,000 and €270,000.Financials
- Is KARIPHARMA profitable?
- In financial year 2025, KARIPHARMA made a profit of €108,353.
- Where can I find the annual accounts of KARIPHARMA?
- KARIPHARMA filed 22 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of KARIPHARMA due?
- KARIPHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.